A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent trial. The study enhances Lilly's position in the obesity drug market, highlighting Zepbound's effectiveness compared to Wegovy,

As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very best weight loss drug for them and their bodies